June 6, 2013
OHSU Knight Cancer Institute Director Brian Druker, M.D., was awarded the 2013 Taubman Prize for Excellence in Translational Medical Science from the University of Michigan’s A. Alfred Taubman Medical Research Institute.
The $100,000 prize honors Druker’s lifesaving breakthrough in treating the genetic cause of chronic myeloid leukemia – research that led to the development of Gleevec® and proved it was possible to target cancer causing cells without harming healthy ones. He shares the prize with Charles Sawyers, M.D., of the Memorial Sloan-Kettering Cancer Center. Sawyers’ research helped drive development of a second wave of drugs for patients who develop resistance to Gleevec.
The Taubman Prize is awarded annually and reserved for clinician-scientists who have worked to transform laboratory discoveries into impactful clinical treatments for diseases. A committee comprised of top-level physicians and leaders from medical centers across the country select the honorees each year.
Druker will present a keynote address at the institute’s 2013 annual symposium on Oct. 11 in Ann Arbor, Mich., where he and Sawyers will be awarded the Taubman Prize trophy. Druker and Sawyers are only the second recipients of the prize, which was awarded last year to Johns Hopkins University geneticist Harry Dietz, M.D., for his progress toward understanding aortic aneurysm and related tissue disorders.